Cargando…

Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches

The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarro, Carla, Ortega, Ángel, Santeliz, Raquel, Garrido, Bermary, Chacín, Maricarmen, Galban, Néstor, Vera, Ivana, De Sanctis, Juan Bautista, Bermúdez, Valmore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227908/
https://www.ncbi.nlm.nih.gov/pubmed/35745875
http://dx.doi.org/10.3390/pharmaceutics14061303
_version_ 1784734301781229568
author Navarro, Carla
Ortega, Ángel
Santeliz, Raquel
Garrido, Bermary
Chacín, Maricarmen
Galban, Néstor
Vera, Ivana
De Sanctis, Juan Bautista
Bermúdez, Valmore
author_facet Navarro, Carla
Ortega, Ángel
Santeliz, Raquel
Garrido, Bermary
Chacín, Maricarmen
Galban, Néstor
Vera, Ivana
De Sanctis, Juan Bautista
Bermúdez, Valmore
author_sort Navarro, Carla
collection PubMed
description The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer.
format Online
Article
Text
id pubmed-9227908
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92279082022-06-25 Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches Navarro, Carla Ortega, Ángel Santeliz, Raquel Garrido, Bermary Chacín, Maricarmen Galban, Néstor Vera, Ivana De Sanctis, Juan Bautista Bermúdez, Valmore Pharmaceutics Review The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer. MDPI 2022-06-19 /pmc/articles/PMC9227908/ /pubmed/35745875 http://dx.doi.org/10.3390/pharmaceutics14061303 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Navarro, Carla
Ortega, Ángel
Santeliz, Raquel
Garrido, Bermary
Chacín, Maricarmen
Galban, Néstor
Vera, Ivana
De Sanctis, Juan Bautista
Bermúdez, Valmore
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
title Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
title_full Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
title_fullStr Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
title_full_unstemmed Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
title_short Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
title_sort metabolic reprogramming in cancer cells: emerging molecular mechanisms and novel therapeutic approaches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227908/
https://www.ncbi.nlm.nih.gov/pubmed/35745875
http://dx.doi.org/10.3390/pharmaceutics14061303
work_keys_str_mv AT navarrocarla metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches
AT ortegaangel metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches
AT santelizraquel metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches
AT garridobermary metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches
AT chacinmaricarmen metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches
AT galbannestor metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches
AT veraivana metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches
AT desanctisjuanbautista metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches
AT bermudezvalmore metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches